ScreenerHero

LXEO Lexeo Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · lexeotx.com
3.310USD+0.30%Mkt Cap: 271.71M $P/E: —

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene the…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap271.71M USD
Enterprise Value65.85M USD
Revenue (TTM)—
Gross Profit-66.64M USD
Net Income (TTM)-99.96M USD
Revenue/Share—
Last Price3.310 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.42
PEG—
EV/EBITDA-0.70
EV/Revenue—
P/S—
P/B1.10
EPS (TTM)-1.02
EPS (Forward)-1.36
52W Range
2.9804% of range10.99
52W High10.99 USD
52W Low2.980 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-40.52%
ROA-37.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-98.56M USD
CapEx (TTM)397.00K USD
FCF Margin—
FCF Yield-21.64%
Net Debt-204.89M USD
Net Debt/EBITDA2.17
Balance Sheet
Debt/Equity0.03
Current Ratio13.89
Quick Ratio13.57
Book Value/Sh2.99 USD
Cash/Share2.58 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.30 USD
Upside (mean)+513.3%
Target Range9.000 USD – 30.00 USD
9.000+513.3% to mean30.00
# Analysts10
Ownership
Shares Out.82.09M
Float51.21M
Insiders0.64%
Institutions114.50%
Short Interest
Short Ratio29.4d
Short % Float29.32%
Short % Out.25.13%
Shares Short20.63M
Short (prev mo.)20.48M
Technical
SMA 504.397 (-24.7%)
SMA 2005.846 (-43.4%)
Beta1.64
S&P 52W Chg16.45%
Avg Vol (30d)1.41M
Avg Vol (10d)2.62M
Technical Indicators
RSI (14)33.4
MACD-0.3326
MACD Signal-0.3141
MACD Hist.-0.0185
BB Upper4.764 USD
BB Middle3.793 USD
BB Lower2.823 USD
BB Width51.19%
ATR (14)0.2865 USD
Vol Ratio (20d)0.67x